New Delhi: Dr Reddy's Laboratories Ltd on Wednesday announced the launch of its oral semaglutide biosimilar, indicated for Type 2 diabetes mellitus, in India under the Obeda brand.
This launch follows Dr Reddy's recent generic semaglutide injection launches in India and Canada, Dr Reddy's Laboratories Ltd (DRL) said in a statement.